BioSpace News Archive

Clarion Medical Technologies, a leading Canadian provider of medical and aesthetic equipment and consumables, is pleased to be the Canadian partner to Evolus, Inc.'s

The Honourable Ginette Petitpas Taylor, Federal Minister of Health, today tabled the 2017 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the House of Commons and the Senate.

DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today that it has acquired TypeZero Technologies, Inc. (“TypeZero”).

Bryant University’s Master of Science in Physician Assistant (PA) Studies program is the first in Rhode Island to be granted full accreditation by the Accreditation Review Commission on Education for the Physician Assistant, Inc. (ARC-PA), earning “Accreditation-Continued” status.

Ultradian Diagnostics LLC, based in Rensselaer, New York, announced the results of a 5-day clinical study of their Biologue minimally invasive continuous glucose monitoring (CGM) system.

BBT-877 demonstrated the best-in-class potential at the preclinical experiments in comparison with competing compounds

CathWorks announced that it has submitted its CathWorks FFRangio™ System to the United States Food & Drug Administration (FDA) for review and 510(k) market clearance.

ABEC becomes the only biopharmaceutical systems supplier with China Manufacture Licenses on two continents

Glaukos Corporation(NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 5, 2018, at 1:15 p.m. EDT in Boston, MA.

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI® (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC).